Zhang et al. demonstrated that CD24 plays a role in trastuzumab-resistant HER2-expressing breast tumors through excessive activation of Src [99], suggesting that CD24 dependent activation of Src links to chemoresistance. Here, SRC is linked to breast neoplasm.